Consistent with the notion that some population of LC3-II is degraded in lysosomes [34], treatment with lysosomal enzyme inhibitors Pepstatin A resulted in the accumulation of LC3-II in cancer cells (Fig 7C), this phenomenon was also impaired while constitutive active Akt ectopic expression. The gene discussed is AKT1; the disease is cancer.